(Q43582725)

English

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

scientific article published in May 2001

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Cocquyt V

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Van Belle S

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Reinhardt RR

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Decramer ML

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

O'Brien M

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Schellens JH

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Borms M

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Verbeke L

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Van Aelst F

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

De Smet M

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Carides AD

11

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Eldridge K

12

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Gertz BJ

13

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

835-842

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life studies in chemotherapy-induced emesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Emesis as a Critical Problem in Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The management of chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropharmacology of Chemotherapy-induced Emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of 5-hydroxytryptamine uptake on the apparent 5-hydroxytryptamine antagonist potency of metoclopramide in the rat isolated superior cervical ganglion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurotransmitter functions of mammalian tachykinins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900416-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(00)00416-0

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43582725&oldid=2101651273"